Dudediligence.

Artiva Biotherapeutics, Inc

ARTVNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

48.9M

on 2026-07-31, from 24.3M on 2024-08-15 10-Q ↗

a raise that quarter, at its price

20M40MAug2024OctMar2025AprJulOctFeb2026AprJul$11.52

Newest

$400.0M

S-3 of 2026-08-06. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

$100.0M

Leerink Partners, agreement of 2025-08-06. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

18.6 quarters

$349.4M on 2026-06-30 ÷ $18.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-05-08Public offering incl. 2.17M pre-funded26,041,664$11.52$300.0M424B5 ↗